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Abstract: Alternative splicing is a key molecular mechanism for increasing the functional diversity of the eukaryotic pro-
teomes. A large body of experimental data implicates aberrant splicing in various human diseases, including cancer. Both 
mutations in cis-acting splicing elements and alterations in the expression and/or activity of splicing regulatory factors 
drastically affect the splicing profile of many cancer-associated genes. In addition, the splicing profile of several cancer-
associated genes is altered in particular types of cancer arguing for a direct role of specific splicing isoforms in tumor pro-
gression. Deciphering the mechanisms underlying aberrant splicing in cancer may prove crucial to understand how splic-
ing machinery is controlled and integrated with other cellular processes, in particular transcription and signaling path-
ways. Moreover, the characterization of splicing deregulation in cancer will lead to a better comprehension of malignant 
transformation. Cancer-associated alternative splicing variants may be new tools for the diagnosis and classification of 
cancers and could be the targets for innovative therapeutical interventions based on highly selective splicing correction 
approaches. 
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INTRODUCTION 
  During evolution the number of genes stopped growing 
in parallel with the complexity of the proteome. Thus, the 
human genome contains only 20.000 - 25.000 genes (Inter-
national
 Human Genome Sequencing Consortium 2004 [1]), 
a number not significantly different from that counted in less 
complex organisms such as sea urchin (23,000) (Sea Urchin
 
Genome Sequencing Consortium 2006) and the nematode 
worm (19,000)
 [2]. Moreover, the number of human genes is 
not sufficient to account for all the proteins revealed by pro-
teomic analysis. How can these paradoxes be explained? 
Recent cDNA sequencing and microarray data have impli-
cated alternative splicing (AS) as the main source of proteo-
mic and functional diversity in metazoan organisms [3]. To-
gether with alternative promoters and polyadenylation sites, 
RNA editing and post-translational processing, AS gives rise 
to an estimated number of at least 100,000 different human 
proteins. 
  The term “alternative splicing” describes any situation in 
which a single primary transcript (pre-mRNA) can be spliced 
in more than one pattern to generate multiple, distinct mature 
mRNAs leading to expression of protein isoforms with dif-
ferent structural and functional properties. The "record-
holder" for alternative splicing is a Drosophila gene called 
Dscam, with 38,000 splice variants, more than the number of 
Drosophila genes [4]. In humans at least 70% (and this pro-
portion might be even higher!!) of the genes encode for tran-
scripts that undergo alternative splicing [5], which under-
scores the importance of this regulatory mechanism in the 
biology of our species.  
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  Because of its capacity to generate protein diversity, al-
ternative splicing is expected to play a major role in gene 
expression regulation, a prediction which is substantiated by 
the observation that appropriate spatio-temporal generation 
of splicing variants is involved in many cellular and devel-
opmental processes (including sex determination, apoptosis, 
axon guidance, cell excitation and contraction and many 
others). It is not surprising, therefore, that deregulation of 
alternative splicing programs is tightly linked to inherited 
and acquired human genetic disorders [6]. Indeed, works in 
the last few years have started to recognize inappropriate 
alternative splicing as a genetic modifier during tumorigene-
sis [7]. Many cancer-related genes are regulated by alterna-
tive splicing. They encode for proteins involved in all major 
aspects of cancer cell biology, including cell cycle control, 
proliferation, differentiation, signal transduction pathways, 
cell death, angiogenesis, invasion, motility and metastasis 
[8]. A common signature of cancer cells is a general loss of 
splicing fidelity, with the concomitant reorganization of 
splicing profiles, and even switching to specific splicing iso-
forms usually expressed in other cell types. All these events 
may contribute to carcinogenesis [8]. Notably, there are sev-
eral cases of alternative splicing that are restricted to specific 
cancer types, which clearly involves that particular splicing 
isoform in tumor progression [8, 9]. Cancer-specific splicing 
events may be also beneficial to therapy, since they generate 
novel epitopes against which it is possible to raise antibodies 
for immunotherapy. Hence, there is great interest in discov-
ering the effect of alternative splicing on the transcriptome 
complexity in cancer cells and in understanding how this 
regulatory mechanism contributes to tumorigenesis. This 
review discusses (1) the basic mechanisms of alternative 
splicing, (2) the present knowledge on the regulatory mecha-
nisms governing alternative splicing and their deregulation  
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in cancer, (3) the biological consequences deriving from the 
alteration of splicing in some relevant cancer-related genes 
and (4) cancer-associated alternative splicing variants with a 
clear diagnostic/prognostic value that can provide potential 
therapeutic targets. 
ALTERNATIVE SPLICING 
  Eukaryotic genomes are characterized by the presence of 
“interrupted” genes consisting of an ordered succession of 
coding (exon) and non-coding (intron) sequences. In meta-
zoan, particularly in mammals, interrupted genes account for 
the vast majority of the genes. Thus, RNA splicing occurs as 
an obligatory, highly regulated, process. Through pre-mRNA 
splicing, introns are precisely removed and exons are joined 
together to reconstitute the reading frame and to generate 
translatable
 mRNAs that are then exported to the cytoplasm. 
  The splicing machinery (called spliceosome), is the larg-
est molecular machine so far described in the cells being 
composed of five small nuclear ribonucleoproteins (snRNPs 
U1, U2, U4, U5 and U6) and more than 100 different poly-
peptides. The spliceosome recognizes short, poorly con-
served, cis-acting sequence elements at exon–intron bounda-
ries (5’ and 3’ splice sites also known as “donor” and “ac-
ceptor” sites) and use them for the cut-and-paste reaction 
(two sequential trans-esterifications) that removes the intron. 
  By using various combinations of donor and acceptor 
sites from different exons, through the process of alternative 
splicing it is possible to produce distinct mRNAs from a sin-
gle pre-mRNA. Five distinct alternative splicing patterns 
have been observed: 1) a regulated (cassette) exon, which is 
sometimes included and sometimes excluded from the 
mRNA; 2) multiple cassette exons that are mutually exclu-
sive, i.e. the mature mRNA always contains only one of sev-
eral possible exon choices; 3) in rare cases, a whole intron is 
retained; 4) alternative donor and 5) acceptor sites can result 
in exons of different size (see Fig. 1). Finally, alternative 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Cis-acting sequences required for the splicing reaction and different types of alternative splicing events. (A) Splicing consen-
sus sequences of a typical eukaryotic gene (exon/intron splice site signals, branch site and polypyrimidine tract). (B) Alternatively spliced 
mRNAs result from exon skipping, intron retention, usage of alternative 3’- (acceptor) or 5’- (donor) sites and from selection of mutually 
exclusive exons. At the protein level, alternative splicing drastically affects the amino acid sequence by deletion or insertion of domains, 
frame-shifts or stop codons. Alternative splicing in non-coding regions of the mature mRNA might impact on translation and mRNA stability. 558    Current Genomics, 2008, Vol. 9, No. 8  Ghigna et al. 
promoters and poly-adenylation sites contribute to the het-
erogeneity of transcripts encoded by a single gene. In addi-
tion to modifying protein features, alternative splicing can 
affect the stability of transcripts through the nonsense-
mediated mRNA decay (NMD) pathway, an mRNA quality-
control mechanism which depends on the translation ma-
chinery [10]. Recent analyses suggest that approximately 
35% of all alternative splicing events in mammalian cells 
generate mRNA species containing premature termination 
codons (PTCs), which can be efficiently degraded through 
NMD [11]. Interestingly, Ni et al. [12] have recently shown 
that exons containing a stop codon are particularly frequent 
and conserved in genes for splicing factors involved in splic-
ing choices. These exons frequently overlap ultraconserved 
elements in mammalian genomes. 
  From a mechanistic point of view the different types of 
alternative splicing can be simply viewed as a problem of 
splice-site recognition by the spliceosome where the decision 
between inclusion and skipping of a particular exon mainly 
depends on the recognition and utilization of the splice sites 
that flank the exon. Alternatively spliced exons are often 
characterized by short and degenerate splice sites. The intrin-
sic weakness of these sites, which reflects the reduced affin-
ity for spliceosomal proteins, is the main cause of alternative 
splicing. The recognition of alternative exons is modulated 
by an additional layer of information provided by an exten-
sive and complex arrays of auxiliary cis-acting elements 
(non-splice site RNA sequence elements), referred to as en-
hancers and silencers of splicing that respectively promote 
and inhibit exon recognition (Fig. 2A). These are short regu-
latory elements (~10 nucleotides) that can be found isolated 
or clustered on the pre-mRNA and are present both within 
exons (ESEs, Exonic Splicing Enhancers and ESSs, Exonic 
Splicing Silencers) and introns (ISEs, Intronic Splicing En-
hancer and ISSs, Intronic Splicing Silencers) [13]. The best-
characterized splicing enhancers are typically purine-rich 
and function by providing binding sites for serine-arginine 
(SR) factors, a family (about a dozen) of essential and abun-
dant RNA-binding proteins highly conserved in animal and 
plant cells [14, 15]. SR factors display multiple roles in con-
stitutive and alternative splicing, as well as in other aspects 
of gene expression [16]. All members of this family share a 
modular structure consisting of one or two copies of an N-
terminal RNA-recognition motif (RRM) followed by a C-
terminal domain of variable length rich in alternating serine - 
arginine dipeptides (the RS domain). The RRMs determine 
the RNA-binding specificity, whereas the RS domain medi-
ates specific protein–protein interactions that are essential for 
the recruitment of the splicing apparatus. However, within 
the functional spliceosome also the RS domains may directly 
contact the pre-mRNA. The sequential character of these 
contacts suggests that RS domain interactions with RNA 
promote spliceosome assembly [17]. 
  In addition, serine residues of the RS domain are targets 
of extensive phosphorylation events that influence protein 
interactions [18], and regulate the activity and sub-cellular 
distribution of SR proteins [19]. Although several kinases, 
including SR protein kinases (SRPKs) 1 and 2, CLK/STY, 
dual-specificity tyrosine-regulated kinase, CRKRS, DNA 
topoisomerase I, glycogen synthase kinase-3 and AKT, have 
been shown to phosphorylate SR proteins [19-24], the sig-
nal-transduction pathways that regulate alternative splicing 
are still poorly understood.  
  Several models have been proposed for the function of 
ESEs and SR factors (Fig. 2B). According to one of these 
models, ESE-bound SR proteins promote exon definition by 
directly recruiting the splicing machinery through specific 
protein-protein interactions mediated by the RS domain [13]. 
Another model predicts that the main function of ESE-bound 
SR factors is to antagonize the negative effect on splicing of 
an inhibitory protein that is bound to a juxtaposed silencer 
element (ESS) (inhibitor model) [13]. Exon inclusion or 
skipping is determined by balance of these competing activi-
ties, which in turn reflect by relative concentrations of the 
cognate RNA-binding activator and repressor proteins. 
These models of splicing enhancement are not necessarily 
mutually exclusive, as they might reflect different require-
ments in the context of different exons.  
  Splicing silencers identified to date appear remarkably 
diverse. They may act as binding sites for factors that block 
access of the splicing machinery to a splice site. Among the 
proteins interacting with ESSs and ISSs elements there are 
heterogeneous nuclear ribonucleoproteins (hnRNP), a group 
of RNA-binding proteins initially recognized as factors that 
interact with RNA polymerase II transcripts to form hnRNP 
particles [13]. On two dimensional gels approximately 30 
spots were described, called with alphabet letters from 
hnRNP A1 through U. Similarly to SR factors, hnRNP pro-
teins have a modular structure in which one or more RNA 
binding domains, generally at the N-terminus, are associated 
to different “auxiliary” domains. Three types of RNA bind-
ing domains (RRMs, hnRNP K homology domain and RGG 
domain, a protein region rich in Arg-Gly-Gly repetitions) 
have been identified in hnRNP proteins and shown to pro-
vide a certain level of RNA binding specificity [13]. The 
auxiliary domains are very different in sequence and control 
the sub-cellular localization and the interaction with other 
proteins. RNA binding specificity and protein-protein inter-
actions contribute to the assembly of the ribonucleoprotein 
complexes that are the substrates for the ensuing splicing 
reaction. The mechanism of hnRNPs action depends on the 
position of their binding sites along the pre-mRNA. In addi-
tion to the inhibitor model described above, hnRNPs bound 
to ISSs flanking an alternative exon may cause the exon to 
loop out, resulting in skipping of the exon (Fig. 2C). Alter-
natively, inhibitory factors bound to ESS may polymerize 
along the exon and displace the ESE-bound SR proteins [13, 
25] (Fig. 2C).  
  Only in few cases alternatively spliced exons are con-
trolled by tissue-specific splicing regulators [13]. In the vast 
majority of cases splicing events appear to be controlled by 
the relative abundance and/or activity of widely expressed 
antagonistic SR factors and hnRNP proteins through a com-
binatorial mechanism, with multiple positive and negative 
factors and sequence elements influencing the final outcome 
of the splicing reaction. This is exemplified by antagonistic 
effects on pre-mRNA splicing of SF2/ASF, an SR factor, 
and hnRNP A1 proteins: high levels of SF2/ASF induce 
exon inclusion whereas high levels of hnRNP A1 promote 
exon skipping [26]. Interestingly, the relative expression 
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change during neoplastic lung growth [27]. Another example 
is SRp55 and its antagonistic factor hnRNP I/PTB that con-
trol the splicing profile of the fibroblast growth factor recep-
tor (FGFR1). Skipping of  exon results in the production of 
the FGFR1- isoform which has a higher affinity for fibro-
blast growth factors [28]. Increased expression of this iso-
form correlates with cancer in the pancreas and brain and 
with poor prognosis in breast tumors [29, 30] and its over-
expression promotes tumor formation in nude mice [28]. 
SRp55 binds to a 69-nucleotide ESE and is required for -
exon inclusion while PTB recognizes a sequence upstream of 
the -exon and promotes exon skipping and production of 
FGFR1- [31]. 
  Recent studies indicate that signaling pathways may con-
trol splicing decisions by affecting the sub-cellular distribu-
tion and/or activity of splicing regulators. Many SR factors 
and hnRNP proteins continuously and rapidly shuttle be-
tween the nucleus and the cytoplasm [32], which unveils a 
cytoplasmic function of these proteins, for example in 
mRNA translation. In this regard, Michlewski et al. [33] 
showed that the splicing factor SF2/ASF stimulates transla-
tion initiation by directly recruiting the mammalian target of 
rapamycin (mTOR) to a subset of mRNAs. Notably, several 
stress treatments perturb the nucleo-cytoplasmic distribution 
of some splicing regulators. For instance, exposure of the 
cells to stress stimuli such as osmotic shock or UVC irradia-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Cis- and trans-acting regulatory elements that control alternative splicing and models for the function of splicing enhancers 
and silencers. (A) Alternatively spliced exons are usually characterized by weak splice sites. Recognition of these sites depends on splicing 
regulatory elements: exonic splicing enhancers (ESE) and silencers (ESS) and intronic splicing enhancers (ISE) and silencers (ISS). (B) ESE 
elements are bound by splicing factors of the SR family. Via interactions with proteins of the splicing apparatus, the RS domain of SR factors 
promotes the assembly of the splicesome on the adjacent intron (left). In addition, SR factors can counteract the inhibitory activity of hnRNP 
proteins bound to ESS elements (right). (C) The mechanism of action of the silencer elements depend on the their position along the pre-
mRNA. In some cases, inhibitory factors (for example hnRNP proteins) bind to ISSs sequences flanking an alternative exon and cause loop-
ing out and skipping of this exon (left). Alternatively, inhibitory factors bound to ESSs may polymerize along the exon and displace the ESE-
bound SR proteins (right). 560    Current Genomics, 2008, Vol. 9, No. 8  Ghigna et al. 
tion, results in a marked cytoplasmic accumulation of 
hnRNP A1, concomitant with an increase in protein phos-
phorylation. These effects are mediated by the MKK(3/6)-
p38 pathway and correlate with changes in the alternative 
splicing pattern of an adenovirus E1A pre-mRNA splicing 
reporter [34]. Moreover, several splicing regulators, includ-
ing SF2/ASF, are sequestered in nuclear stress bodies after 
treatments that activate the heat shock response [35]. This 
capacity to modulate the activity of splicing regulators opens 
the exciting possibility that stressing conditions, as those in 
the tumor microenvironment, may influence the splicing 
profile of a number of genes and thus affect cell identity. 
  Our knowledge of the molecular mechanisms underlying 
alternative splicing is still limited. Indeed, there are many 
exonic and intronic elements for which trans-acting media-
tors remain to be identified and, in most of the cases, regula-
tory circuits that control splicing decisions and the link with 
signal-transduction pathways, are not well understood. Deci-
phering the complex regulatory network underlying alterna-
tive splice site choice remains a major challenge in this area 
of research. 
ABERRANT ALTERNATIVE SPLICING IN CANCER-
RELATED GENES 
  Genome wide analyses indicate that ~75% of human 
genes encode at least two alternatively spliced isoforms [5]. 
Thus, alternative splicing seems to be the rule for human 
genes and it is not surprising that splicing defects in specific 
genes are causatively linked to genetic disorders. Well-
characterized examples are spinal muscular atrophy, myo-
tonic dystrophy, retinitis pigmentosa, Frasier syndrome, he-
mophilia A, -thalassemia, atypical cystic fibrosis and some 
neurodegenerative diseases [6]. It has been calculated that 
about 15% of point mutations that cause hereditary diseases 
do alter pre-mRNA processing by affecting canonical 5’ and 
3’ splice sites, branch sites or polyadenylation signals [14, 
36]. This figure is probably an underestimation since it does 
not take into account mutations in splicing regulatory ele-
ments (enhancers and silencer) that may prevent the interac-
tion with splicing regulators (hnRNPs and SR factors). In-
deed, at least 50% of 50 single-base substitutions that cause 
exon skipping in human genes disrupt splicing enhancers 
[14, 36, 37]. Frequently, splicing defects due to gene muta-
tions introduce premature stop codons and target the mRNA 
to degradation by the nonsense-mediated decay pathway 
(NMD) [10]. The final effect is that, instead of a truncated 
polypeptide, no protein is produced.  
  In the last few years a link has emerged between cancer 
development and deregulation of alternative splicing [7, 9]. 
A common feature of cancer cells, in fact, is the general de-
regulation of splicing, which may lead to the expression of 
tumor-specific variants and which is most likely promoted 
by alterations in signaling pathways and by variations in 
concentration, localization and activity of trans-acting splic-
ing regulators  [9, 24]. It is still disputed whether these 
changes in splicing profiles are simply a “noise” occurring in 
cancer cells or have a direct role in tumorigenesis. As a mat-
ter of fact, recent progresses in molecular and cell biology 
indicate that altered splicing profiles of critical genes may 
impact on all the major aspects of cancer cell biology [8, 9]. 
This can be due to inactivation of onco-suppressor [38] or to 
gain of function of proteins implicated in cancer susceptibil-
ity [39] and in tumor progression [8, 9, 40].  
Cis-Acting Mutations 
  These are inherited or somatic mutations that affect the 
splicing process. According to their position and effect on 
splicing, these mutations can be divided into two subclasses. 
Subclass I (60% of cases) comprises splicing mutations in 
the invariant splice-sites and completely abolish exon recog-
nition. These mutations are associated with severe diseases. 
Subclass II is often associated with a relatively mild pheno-
type and includes mutations in the variant motifs (such as the 
alternative splicing poly-pyrimidine tract) and intronic muta-
tions that generate cryptic donor or acceptor sites. An exam-
ple comes from the tumor suppressor p53 gene, i.e. the most 
commonly mutated gene in human cancers. Isoforms of p53 
originate through alternative splicing and differ for their tu-
mor suppressor function [41]. Interestingly, “silent” muta-
tions in the p53 gene are predicted to affect splicing because 
they create splice sites in the middle of an exon [38]. It is 
worth considering, however, that many mutation screenings 
focused on exons and ignored non-coding regions [42]. Be-
low, we discuss other examples of mutations that affect 
splicing of oncogenes and tumor suppressor genes. 
  Mutations in the APC gene result in familiar adenoma-
tous polyposis (FAP). Recently, it has been reported that an 
attenuated form of FAP is caused by an insertion of a single 
T between the second and third position of intron 4 of the 
APC gene that leads to skipping of exon 4 and to the pre-
dicted expression of a truncated protein [43]. Two additional 
mutations in introns 3 and 4 have the identical effect [44]. 
  Also mutations in splicing regulatory elements, such ESE 
and ESS sequences, can perturb splicing profiles. A good 
example is the tumor-suppressor BRCA1 gene that encodes a 
protein involved in a variety of cellular processes including 
transcriptional regulation, recombination, DNA repair [45] 
and cell apoptosis [46]. Mutations in the BRCA1 gene are 
well-known markers of susceptibility to ovarian and breast 
cancer, the last one being the most common malignancy 
among women. Mazoyer et al. [39] demonstrated that an 
inherited nonsense mutation within exon 18 disrupts an ESE 
element (the binding site for the SR factor SF2/ASF) and 
provokes exon skipping. Computer analysis with the ESE-
finder program has identified 23 highly conserved ESEs in 
the 22 exons of the BRCA1 gene [25]. About 60% of these 
motifs contain nucleotide substitutions reported in the Breast 
Cancer Information Core [47] suggesting the possibility that 
targeting of splicing profiles may be the mechanisms through 
which mutations affect the BRAC1 function [47]. The 
BRCA1 gene encodes at least thirty distinct splicing variants 
that are differentially expressed in tissues [48]. Most of the 
alternatively spliced transcripts maintain the open reading 
frame of the original cDNA and have the potential to code 
for functional proteins. Notably, breast and ovarian cells 
express a common set of variants suggesting the intriguing 
possibility that they share some regulatory pathways which 
instead is absent in leukaemia cell lines that display a differ-
ent set of isoforms [49]. Many nonsense mutations in the 
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double point mutation in exon 7 of the neurofibromatosis 1 
(NF1) gene disrupts the consensus binding sites for the SR 
factors, SC35 and SF2/ASF, and promotes exon skipping. 
[50]. The NF1 gene shows one of the highest mutation rate 
among genes associated with human disorders; simply on the 
bases of the DNA sequence, it was predicted that 37% of 
these genomic mutations could determine splicing defects 
[37]. However, when this prediction was verified through the 
analysis of the mature mRNAs, it became evident that up to 
50% of the NF1 gene mutations are associated with splicing 
defects. The negative message emerging from this analysis is 
that we are still unable to infer the splicing profile simply 
from the primary DNA sequence and that we have to rely on 
RNA and even protein sequences to understand the effects of 
any gene mutation [37].  
  Similar observations have been done with a number of 
other tumor-associated genes such as  BRCA2,  FHIT, KIT, 
MLH1, MDM2, MSH2 and LKB1 [43, 51-56]. Notably, all 
these cases, and many others that are continuously described, 
represent an extension of the concept according to which 
cancer progression is due to a number of stable genetic muta-
tions that perturb the structure, the function or the abundance 
of critical proteins. In this sense, splicing defects can be 
viewed as one of routes through which gene mutations cause 
tumorigenesis. However, alternative splicing of oncogenes or 
tumor suppressors could also be affected by mutations in 
splicing regulators which implies an activity of these factors 
as oncoproteins or tumor suppressors, depending on their 
antagonistic functions on splice site selection. For example, 
the SRP55 gene (SFR6) is mutated in breast and colorectal 
cancers [55]. Interestingly, SRp55 controls the splicing pro-
file of several tumor-associated genes, among which CD44 
[57]  and  KIT [58]. Also some hnRNP proteins have been 
classified as oncogenes. In the 90% of the human myxoid 
liposarcomas, the t(12;16) translocation generates a fusion 
between the hnRNP P2 gene, that encoded a multifunctional 
protein involved in transcription, splicing and mRNA export, 
and the CHOP gene, encoding for a CCAAT/enhancer bind-
ing protein implicated in erythropoiesis, adipocyte differen-
tiation, growth arrest and G1-S cell cycle progression. The 
product of the hnRNP P2-CHOP fusion contains the amino 
terminal transcription activation domain of hnRNP P2 and 
the DNA binding domain of CHOP and its over-expression 
in nude mice results in tumor formation [59]. 
Changes in Trans-Acting Factors 
  More interesting, from our point of view, is the observa-
tion, reported by many studies over the last 20 years, that 
most cancer-associated splicing alterations are not associated 
with nucleotide changes in the affected genes, implying 
modifications in the expression and/or activity of splicing 
regulatory factors [9, 40, 60]. Indeed, changes in the reper-
toire of SR factors and hnRNP proteins frequently occur in 
tumors and are accompanied by alterations in the relative 
abundance of alternative splicing products, a typical signa-
ture of cancerous cells with predictable effects on cellular 
behavior [27, 40, 60, 61]. As a matter of fact, cancerous cell 
lines show a high level of alternative splicing events that are 
not conserved between human and mouse and are not ex-
pressed in normal tissues [62] strengthening the idea that a 
change in the level of splicing regulators in cancer cells may 
severely impinge on gene expression programs.  
  A salient example to illustrate how aberrant splicing in 
cancer can be modulated by altered activity or expression of 
splicing factors is provided by CD44, a trans-membrane gly-
coprotein involved cell–cell and cell-matrix interactions [63]. 
Several CD44 isoforms are generated through variable in-
corporation of 10 alternative exons (v1-v10) in its proximal 
extra-cellular domain. Standard CD44, lacking all alternative 
exons, is predominantly express in normal tissues, whereas 
CD44 isoforms, in particular those containing variant exons 
v5, v6 and v7, are over-expressed in various tumors and have 
been implicated in tumor cell invasion and metastasis [63]. 
The production of different CD44 isoforms correlates with 
changes in the abundance of SR proteins [61, 64] and several 
splicing factors ( including hnRNPA1, SRp55, SF2/ASF, 
Tra-2 beta, YB-1 and Sam68) that have been shown to regu-
late specific variant exons [65-68]. Several lines of evidence 
indicate that CD44 splicing is regulated in response to extra-
cellular stimuli. Thus, Matter et al. [68] found that the RNA 
binding protein Sam68 (Src-associated in mitosis 68-kDa) 
promotes v5 inclusion in response to activation of the Ras-
Raf-Mek-Erk pathway. Although mechanistic details are 
incomplete, it has been suggested that the interaction of 
phosphorylated Sam68 with exon v5 blocks the repressive 
activity of hnRNP A1, either by preventing the interaction of 
hnRNP A1 with the ESS element (by steric hindrance), or by 
counteracting the inhibitory effect of hnRNP A1 bound to 
the ESS. Recently, Cheng and Sharp identified SRm160 as 
another Ras-regulated splicing factor responsible for inclu-
sion of v5 exon in CD44 transcripts [69]. Importantly, they 
also showed that silencing of SRm160 decreases cellular 
invasiveness, linking this splicing regulator to tumorigenesis.  
  Another good example of splicing modulation by signal-
ing pathways comes from the Fibronectin gene (FN), an ex-
tra-cellular matrix component and a key determinant in con-
trolling proliferation, migration, invasion and metastatic be-
havior of tumor cells. EDA is a FN splicing isoform gener-
ated by inclusion of a single exon (EDA exon, also known as 
EDI or EIIIA). This splicing isoform is poorly expressed in 
adult normal tissues, whereas it is present in embryos as well 
as during wound healing and in certain tumors. Inclusion of 
the EDA exon is triggered by the activation of the Ras/PI3-
kinase/AKT pathway by growth factors. AKT directly phos-
phorylates the SR proteins 9G8 and SF2/ASF, which in turn 
bind to the EDA exon and promote its recognition by the 
splicing apparatus [24]. Activation of the same pathway by 
insulin regulates the activity of another SR protein, SRp40, 
and stimulates the inclusion of an alternative exon in the 
protein kinase C (PKC) II pre-mRNA [70, 71]. Altogether 
these results support the possibility that deregulation of the 
Ras/PI3-kinase/AKT pathway, for instance resulting from 
mutations in its components, could have dramatic conse-
quences on the splicing profile of any pre-mRNAs regulated 
by 9G8, SF2/ASF, SRp40 and perhaps other SR proteins. An 
attractive hypothesis is that exons responsive to this signal-
ing pathway belong to a set of genes that function coopera-
tively to modulate the cell physiology in accordance with the 
biological role of the signaling molecule. The identification  
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of these exons, therefore, will be of the utmost interest. An 
indication in favor of this hypothesis comes from the obser-
vation that AKT also promotes translation of EDA mRNAs 
bound by phosphorylated 9G8 and SF2/ASF [24]. Thus, ac-
tivation of a single signal-transduction pathway controls in 
an integrated manner both splicing and translation of specific 
mRNAs and stimulates the production of specific proteins. 
The final effect is a drastic increase both in the speed and 
strength of the signaling response as measured by production 
of the induced protein. 
  Although these examples provide interesting insights into 
the effects of signal-transduction pathways on splicing regu-
lation, the molecular characterization is still scanty and clari-
fication of the complete pathway has not yet been provided. 
Thus, in addition to illustrate a role of signal transduction in 
splicing control, these cases also suggest the need of further 
studies to elucidate this important mechanism of gene regu-
lation. 
  An increasing body of data implicates alternative splicing 
as a mechanism to control apoptosis or programmed cell 
death, an essential process in development and in mainte-
nance of cellular homeostasis in multicellular organisms. 
Bcl-X is a member of the BclII family that directs mitochon-
drial breakdown during apoptosis. The usage of alternative 5' 
splice sites within exon 2 determines the production of two 
protein isoforms: a long antiapoptotic form (Bcl-XL) and a 
short apoptosis-promoting protein (Bcl-XS) [72]. Therefore, 
a shift in the splicing pattern of these transcripts can have 
deep effects on proliferative activity of cancer cells and on 
their response to proapoptotic therapies. Several splicing fac- 
tors, including Sam68, SF2/ASF, hnRNP F/H and SAP155, 
contribute in controlling the choice between the two alterna-
tive 5’-splice sites. In particular, Sam68 over-expression 
promotes the production of pro-apoptotic Bcl-XS and this 
effect is reverted upon Sam68 phosphorylation [73]. On the 
contrary, hnRNP F/H proteins, by binding to a G-rich stretch 
element, promote the usage of the Bcl-XS - 5’splice site 
[74]. The ratio of Bcl-X splice variants contribute to deter-
mine the sensitivity of the cells to a wide variety of apoptotic 
agents and may have significance in drugs resistance and 
chemotherapeutic responsiveness. For example, the lipid 
ceramide, a mediator/regulator of apoptosis promotes the 
expression of the pro-apoptotic splicing variants Bcl-XS; the 
choice between the two alternative 5’-splice sites is con-
trolled by a ceramide responsive element (CRCE 1) located 
within exon 2 and bound by SAP155 [75]. Moreover, cera-
mide is able to modulate the phosphorylation status of SR 
proteins in a phosphatase-1 (PP1)-dependent manner [75]. 
Interestingly, one of PP1 targets is the SR factor SF2/ASF, 
another major regulator of Bcl-X pre-mRNAs processing 
[76].  
  There are several examples of alternative splicing events 
that control the activity of proteins involved in cell motility 
and invasion, a pre-requisite for the formation of cancer me-
tastases. This is the case of splicing isoforms of the andro-
gen and estrogen receptors that are involved in mammary 
carcinomas  [77, 78]. Interestingly, an isoform of estrogen 
receptor alpha, due to skipping of exon 3 (delta3ER), is a 
more potent activator of vascular endothelial growth factor 
than the wild-type receptor [79]. The splice variant Rac1b, 
which is generated by inclusion of a 57-nucleotide cassette 
exon, has been shown to lead to anchorage-independent cell 
growth. Notably, Rac1b is up-regulated in colorectal tumors 
at various stages of neoplastic progression, as compared to 
adjacent normal tissues [80]. Other examples, that clearly 
show the potential functional effect of aberrant splicing on 
tumorigenesis, are the fibroblast growth factor receptor 2 
(FGFR2) [81], the fibronectin [82] and the survivin [83]. 
  Recently, we have used the Ron (recepteur d’origine nan-
tais) proto-oncogene as a model to investigate the relation-
ship between alternative splicing and tumor progression [40]. 
Ron, the human tyrosine kinase receptor for the macrophage-
stimulating protein (MSP), is a heterodimeric protein (p185-
Ron) composed of  and  subunits both deriving from the 
processing of a common precursor. Binding to MSP stimu-
lates the intrinsic tyrosine kinase activity of Ron and results 
in phosphorylation of its docking site for multiple transducer 
and adaptor proteins leading to the activation of signaling 
cascades (Fig. 3A). Along with Met, the hepatocyte growth 
factor (HGF) receptor, Ron belongs to a subfamily of recep-
tor tyrosine kinases (RTK) with unique expression patterns 
and biological activities. In addition to promoting cell 
growth and protection from apoptosis, these receptors con-
trol cell dissociation, motility, and invasion of extracellular 
matrices, a process known as ‘‘invasive growth’’ or ‘‘cell 
scattering’’ [84]. Invasive growth is physiologically relevant 
during development, organogenesis and tissue regeneration, 
but it is also important to mediate invasiveness and to pro-
mote malignant progression. Currently, six variants includ-
ing Ron170, 165, 160, 155, 110, and 55 with vari-
ous deletions or truncations in the extracellular or intracellu-
lar regions have been identified. All these variants are consti-
tutively active but differ in their biochemical and biological 
properties [for review see [85]]. Moreover, the splicing pro-
file of the Ron gene is frequently altered in epithelial can-
cers, such as colon and breast cancers, suggesting that the 
production of multiple Ron isoforms could contribute to 
pathogenesis of these tumors [40, 86]. Over-expression of 
any of these isoforms increases cell motility (scatter-like 
activity). However, only Ron160 or Ron155 are able to 
induce focus formation, sustained anchorage-independent 
growth and the ability to form metastatic tumors in mice 
[86]. This oncogenic potential is channeled through the PI3-
Kinase/AKT pathway [87].  Also Met transcripts undergo 
alternative splicing and an isoform, called Met-SM, origi-
nates from skipping of exon 14 which encodes a 47 amino-
acid segment in the juxtamembrane domain. This isoform 
has been recently shown to play an important role in devel-
opment and progression of human cancers [88]. Among the 
mechanisms controlling the expression of the different Ron 
isoforms in cancer cells, the switch from constitutive to al-
ternative splicing plays the major role. Thus, the elucidation 
of the regulatory pathways controlling the splicing profile of 
Ron transcripts will shed new light on both cancer initiation 
and progression. We have studied in detail the alternative 
splicing event that leads to the production of Ron mRNA. 
This transcript lacks a 147-bp exon (exon 11). The encoded 
protein bears a 49-amino-acid in frame deletion in the extra-
cellular domain that affects the proteolytic maturation and 
results in the accumulation of a single-chain pro-Ron165 in 
the cytoplasm. Moreover, the deleted protein is characterized Alternative Splicing and Tumor Progression  Current Genomics, 2008, Vol. 9, No. 8    563 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Schematic representation of the Ron receptor and of the downstream signalling pathways. (A) Ron is a single-pass, disulfide-linked 
/ heterodimer. The  chain is an extracellular glycoprotein while the chain is a transmembrane subunit that comprises an extra-cellular sequence, 
a short trans-membrane segment, a large cytoplasmic portion with intrinsic tyrosine kinase domain (TK) and a C-terminal tail. Residues and domains 
important for the Ron activity are indicated. In particular, the intracellular domain includes the tyrosine kinase catalytic site (white oval) flanked by 
distinctive juxtamembrane and carboxy-terminal sequences. Phosphorylation of two tyrosines within the kinase domain positively regulates the en-
zyme activity, whereas a serine residue in the juxtamembrane domain has a negative regulatory role. Two tyrosine residues in the carboxy-terminal 
region, when phosphorylated, form a specific docking site for multiple signal transducers and adaptors. Activation of Ron by MSP can initiate signal-
ing through many pathways implicated in tumor progression and metastasis, such adhesion, invasion, mobility, proliferation and inhibition of apopto-
sis. (B) The constitutively active Ron isoform is generated through skipping of exon 11. This event is controlled by two adjacent splicing elements, a 
silencer and an enhancer, located in the central part and at the 3’ end of exon 12, respectively. These two regulatory elements may form a ‘‘control 
cassette’’ that tunes the strength of the acceptor site of intron 11 and thus the ratio between Ron and Ron transcripts. Splicing factor SF2/ASF di-
rectly binds to the enhancer and governs its activity. High levels of SF2/ASF increase the strength of the acceptor site of the intron 11, promote the 
production of Ron isoform and trigger morphological and molecular changes typical of the epithelial to mesenchymal transition (EMT). The primary 
function of the silencer could be to antagonize the enhancer and prevent exon skipping. 564    Current Genomics, 2008, Vol. 9, No. 8  Ghigna et al. 
 
by aberrant intracellular disulfide bridges that facilitate 
Ron165 oligomerization leading to constitutive phosphory-
lation and activation [89]. We have shown that the choice 
between inclusion and skipping of exon 11 is controlled by 
two adjacent regulatory elements, a silencer and an enhancer, 
both located in the constitutive exon 12 (Fig. 3B) [40]. The 
binding of the SR protein SF2/ASF to ESE stimulates skip-
ping of exon 11 and the production of Ron. Thus, over-
expression of SF2/ASF in cells that normally express Ron 
triggers the production of the Ron165 with dramatic conse-
quences on the cell properties. Indeed, similarly to what ob-
served after Ron over-expression, an increased expression 
of SF2/ASF profoundly affects cell morphology and triggers 
nuclear accumulation of -catenin, reorganization of actin 
cytoskeleton, and down-regulation of E-cadherin, a tumor 
and invasion suppressor in human carcinomas. All these 
morphological and molecular changes represent hallmarks of 
the epithelial to mesenchymal transition (EMT), which is 
implicated in the metastatic spreading of human carcinomas 
(Fig. 3B) [90]. Notably, knockdown of SF2/ASF by RNA 
interference (RNAi) reduces the levels of Ron and con-
comitantly decreases cell motility. Similarly, RNAi specifi-
cally directed against Ron reduces cell motility and par-
tially reverts the morphological changes induced by SF2/ 
ASF over-expression. 
  Given the reported up-regulation of several SR proteins, 
including SF2/ASF, during tumor progression [27, 60], it is 
tempting to speculate that splicing factor SF2/ASF could 
promote the malignant transformation by inducing a Ron-
mediated EMT. This hypothesis is consistent with a recent 
report showing that SF2/ASF behaves as a bona fide proto-
oncogene [60]. SF2/ASF is up-regulated in a set of human 
tumors and, the gene coding for SF2/ASF is specifically am-
plified in some breast tumors but not in normal breast tissue 
from the same patient. Limited over-expression of SF2/ASF, 
comparable to that in cancer samples, resulted in tumor for-
mation in nude mice. Notably, several endogenous splicing 
targets of SF2/ASF, among them a novel oncogenic isoform 
of the mTOR substrate, S6K1, are essential for SF2/ASF-
mediated transformation. In addition, RNA interfering 
(RNAi) of SF2/ASF or the oncogenic S6K1 isoform, re-
sulted in reversion of the transformed phenotype [60]. 
  The identification of splicing regulators as a novel class 
of proto-oncogenes may unveil novel aspects of cancer biol-
ogy and offer new opportunities for diagnosis and therapy. 
  Although all the examples reported above unquestionably 
prove that changes in the splicing activity of tumor cells is 
linked tumor progression, yet the molecular mechanisms 
responsible for these changes remain undefined. Several 
questions still deserve investigation. Which are the events 
that lead to deregulation of expression and/or activity of 
members of SR and hnRNP families? Is there a generalized 
reorganization of the splicing machinery in cancers cells or 
does the splicing switch result from a deregulation of a sub-
set of splicing regulators? How do signal transduction path-
ways cooperate to affect splicing profiles to determine ma-
lignant conversion? 
Alternative Splicing Signatures as Potential Diagnos-
tic/Prognostic Indicators and Prospect for Therapies 
  In the previous sections we have discussed several exam-
ples that illustrate a causative link between alternative splic-
ing and development of neoplasia. It is worth noticing that in 
many cases splicing isoforms appear to be cancer-specific 
[8]. Moreover, there are evidences that in different tissues a 
different set of genes undergoes changes of splicing profiles 
during tumorigenesis [91]. Thus, in kidney tumors, Tropo-
myosin 1, Actinin  1, Integrin  4, Catenin  1 and Fibro-
blast growth factor receptor 2 change their alternative splic-
ing patterns, whereas N-glycanase1 does not, despite its ap-
parent alterations in lung and uterus tumors. These findings 
argue against the idea that changes in splicing profiles may 
result from a generalized alteration of splicing machinery in 
cancers cells and suggest that only a specific set of splicing 
regulators are affected by the tumorigenesis in a tissue-
specific manner. The identification of cancer-specific, tissue-
specific alternatively spliced isoforms immediately incited 
their potential use as diagnostic, prognostic, or predictive 
biomarkers [8]. Although large-scale studies have yet to be 
carried out, initial results are promising. An important corre-
lation between aberrant alternative splicing and tumor pro-
gression has been shown for CD44 [63]. In particular, the 
isoforms containing the variant exon v6 are frequently up-
regulated in head and neck carcinomas or in advanced stage 
gastric cancers and CD44v6 positive tumors are associated to 
poor prognosis [92]. Also, aberrant alternative splicing of 
MDM2 transcripts were found to associate with a prognostic 
factor for poor survival in patients with breast cancer [93], 
whereas HDMX has been linked to soft-tissue sarcoma [94]. 
Furthermore, altered expression of a spliced variant of p73, a 
p53-related protein, seems to be a negative prognostic 
marker in patients with neuroblastoma [95]. 
  During the past decade classical gene expression profil-
ing performed by microarray has been a powerful tool for the 
discovery of new cancer biomarkers. However, most array 
platforms developed to date are not designed to distinguish 
mRNA isoforms. An important direction for the future will 
be the application of genome-wide screens designed for the 
analysis of alternative splicing signatures associates with 
cancer but virtually absent in normal cells. These splicing-
sensitive microarrays have the potential to better identify 
tumor sub-classes. Moreover, they do not require that cause–
effect relationships between splicing profiles and cancers are 
identified (or even that they existed!!), but only that this as-
sociations are sufficiently consistent to be predictive. Inter-
estingly, Li et al. [96] have used an approach to simultane-
ously quantify changes in splicing (“splicing switch”) and 
transcript abundance (up- and down-regulation). The advan-
tage of this “two-dimensional’’ profiling strategy is that it 
works with partially degraded biological samples such as 
RNA derived from tissue blocks that have been formalin-
fixed and paraffin-embedded. These authors identified a spe-
cific set of mRNA isoform biomarkers for prostate cancer 
using independent panels of tissue samples. In particular, 
they reported two variants of AMACR gene (which encodes 
a-methylacyl-CoA racemase) resulting from the alternative 
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tion: one isoform showed a quantitative up-regulation in 
prostate cancer compared with normal prostatic tissues, the 
other seemed to be expressed only in prostate cancer. More 
recently,  novel microarray technology has been used to 
measure whole-genome exon expression in 102 normal and 
cancer tissue samples of different stages from colon, urinary 
bladder, and prostate [97]. Seven genes with tumor-specific 
splice variants were identified (Alpha-actinin 1, Caldesmon, 
Collagen, type VI alpha 3, Leucine-rich repeat interacting 
protein 2, Phosphatidylinositol-4 kinase catalytic beta poly-
peptide,  Tropomyosin 1 and Vinculin). Notably, tumor-
specific splicing patterns of Alpha-actinin 1, caldesmon and 
Vinculin, key cytoskeleton components, were found in all 
three organs suggesting that they may represent general can-
cer related splicing events. Moreover, in silico protein analy-
sis predicts that these identified cancer-specific splice vari-
ants encode proteins with potentially altered functions, indi-
cating that they may be involved in pathogenesis and hence 
represent novel potential biomarkers and drug targets [97].  
  Cancer-specific splice variants may not only serve as 
diagnostic and prognostic tumor markers, but also provide 
potential targets for the development of new therapeutic 
strategies (Fig. 4). One promising avenue towards the devel-
opment of more selective anticancer drugs consists in tar-
geted delivery of bioactive compounds to the tumor by 
means of molecules (for example antibodies) that are spe-
cific for tumor-associated markers. The accessibility as well 
as the restricted pattern of expression of the antigene is an 
important criterion in the selection of a target for bio-mole- 
cular intervention. Notably, many receptors mediating cell-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Potential use of therapeutic approaches that target alternative splicing. Various strategies are currently being used to exploit 
alternative splicing for treatment of cancer. (A) In many cases, cancer-restricted splice variants contain unique epitopes that could be used as 
the targets for specific antibodies conjugated to tumor-cell toxins. (B) Many chemical compounds have been found to affect splicing of nu-
merous genes. Although the mechanisms by which splicing patterns are altered are still poorly understood, several compounds are able to 
block the activity of SR-protein kinases (SRpKs) and, consequently, reduce the phosphorylation state of SR splicing factors. (C) Syntheti-
cally modified oligonucleotides, such as phosphorothioate, morpholino phosphorodiamide and 2´-O-methylethyl, are able to block the inter-
action of the spliceosome machinery with a specific site. Moreover, they are more stable and active than regular nucleotide backbones and 
display low toxicity in vivo. (D) Cancer-specific mRNA transcripts that contain unique sequences can be targeted using RNAi mediated deg-
radation.  566    Current Genomics, 2008, Vol. 9, No. 8  Ghigna et al. 
cell and cell-matrix interactions are regulated by alternative 
splicing and specific alternatively spliced variants of these 
molecules are associated with many human malignancies [8, 
9]. Interestingly, nearly 90% of alternative splicing events 
affect regions located on the exposed surface of protein [98] 
and for many cell membrane molecules, alternative exons 
encode novel epitopes that are usually found in the extra-
cellular domain of the protein [8, 9]. These epitopes seem to 
be ideally suited for tumor-targeting strategies. Once more, 
the CD44 protein, discussed in detail in the previous section, 
provides a remarkable example since radiolabeled antibodies 
directed against the CD44-v6 isoform appear to offer a 
promising therapeutic tool and are currently in clinical trials 
for treatment of head and neck cancer [99]. However, despite 
these promising developments, solid tumors are frequently 
relatively resistant to antibody-based therapies [100]. This is 
due, in part, to the relative inaccessibility of tumor cells and 
to the poor penetration of antibodies into the tumor tissue. 
Since tumor cells are separated from the blood by endothe-
lial cells and extracellular matrix components surrounding 
the vasculature, tumor uptake is highly limited by the anti-
body’s ability to cross this layer. Importantly, therapeutic 
approaches directed against tumor neo-vasculature have 
gained significant for a number of reasons: (i) tumor vascu-
lar endothelial cells are readily accessible for drugs via the 
blood circulation; (ii) there is growing evidence that inhibi-
tion or regression of tumor vessels leads to cancer cell death 
since they rely on blood vessels for nutrients and oxygen to 
satisfy their metabolic needs [101]. An interesting example 
is the EDB alternatively spliced isoform of Fibronectin (FN). 
The EDB isoform is generated through inclusion of a single 
exon encoding a 91 amino acids region and it is present in 
neoplastic tissue blood vessels while it is virtually absent in 
mature/adult tissues. EDB is involved in the regulation of 
endothelial cell proliferation and vascular morphogenesis; an 
EDB–specific radiolabeled antibody is currently on phase II 
clinical trials for anti-angiogenic cancer treatment [102]. 
Recently, it has been shown that the alternatively spliced 
extra-domain A (EDA) of fibronectin may represent another, 
equally attractive, target for the antibody-based delivery of 
bioactive agents to the neovasculature not only of solid tu-
mors, but also of metastatic lesions [103]. Similarly, splicing 
variants could represent novel leukemia-specific antigens 
with potential use in immunotherapeutic approaches. In Ph-
positive leukemias, the t(9;22) translocation generates the 
Bcr/Abl fusion proteins, whose constitutive tyrosine kinase 
activation is responsible for the appearance of the leukemia 
phenotype [104]. In addition to the main BCR/ABL fusion 
transcripts, it has been reported that BCR/ABL transcripts, 
arising from alternative splicing, are also produced in a high 
percentage of chronic myelogenous leukemia (CML) and 
acute lymphoblastic leukemia (ALL) patients [105]. In par-
ticular, BCR/ABL alternative transcripts involving ABL exon 
4 are very attractive because the resulting fusion proteins 
contain a novel immunogenic epitope that is able to elicit an 
antigen-specific T-cell response [105].  
  Innovative therapeutic approaches could also be designed 
to target the splicing machinery. For example, post-transla- 
tional modifications of splicing regulators may be relevant 
for tumor progression. SRPK1 is up-regulated in breast and  
 
colonic tumors compared with adjacent normal epithelium, 
and the levels of the kinase increase along with tumor grade 
[106]. Strong expression of SRPK1 protein was also evident 
in the majority of breast and colonic tumor cell lines [106]. 
Interestingly, down-regulation of SRPK1 using small inter-
fering RNA (siRNA) affects the expression of key apoptotic 
factors BAX and BCL2, increases the proportion of the tu-
mor cells (but not of nontrasformed cells) undergoing apop-
tosis and amplifies their sensitivity to two commonly used 
chemotherapeutic agents such as gemcitabine and cisplatin. 
[106, 107]. These results suggest that pharmacological inhi-
bition of SRPK1 activity may be effective as stand-alone 
agent or in combination with conventional chemotherapeutic 
regimens. Moreover, small molecules with SRPK-blocking 
activity, such as Clk1/Sty inhibitors [108] or potent inhibi-
tors of the splicing reaction, such as indole derivatives [109], 
can be used to alter splicing patterns. Interestingly, recent 
data showed that the spliceosomal protein E (SmE) functions 
as suppressor of tumor cell growth in p53-independent man-
ner [110]. Thus, considering that a large portion of human 
cancers are defective in p53 activity, targeting SmE in cancer 
gene therapy will be of particular interest. 
  Different therapeutic approaches are currently being ex-
plored to correct aberrant alternative splicing at the RNA 
level. These strategies can either alter alternative splicing 
patterns of specific genes or recognize particular mRNA 
species to elicit their degradation (for example, RNAi, mi-
croRNA and ribozymes). Correction of splicing defects 
through manipulation of mRNA requires the use of gene-
therapy strategies, which are often connected with problems 
such as delivery, toxicity and immunogenicity. SiRNA-based 
therapy has shown great promise for many diseases such as 
cancer. Major targets for siRNA therapy include oncogenes 
and genes that are involved in angiogenesis, metastasis, cell 
survival, antiapoptosis and resistance to chemotherapy [111]. 
Moreover, the latest generations of antisense oligonucleo-
tides that contain chemical modifications appear more stable 
compared to conventional nucleotide backbones. Some of 
these oligos prevent ribosomal assembly, and hence mRNA 
translation, and seem to be well tolerated in patients [112]. In 
addition, synthetically modified oligonucleotides targeted 
through sequence specific hybridization to splice sites or 
adjacent sequences may block inappropriate exon selection 
by inhibiting the binding of trans-acting factors. They have 
been successfully applied to correct aberrant splicing of -
globin, CFTR, dystrophin, tau genes [113] and to repress the 
generation of cancer-related splice variants of FGFR1, Bcl-
X, and MDM2. Alone or in combination with chemothera-
peutic agents, such as cisplatin, irinotecan, paclitaxel, 
fluorouracil they may proficiently used in therapy [114]. 
Finally, we have designed a phosphorodiamidate morpholino 
oligomer targeting the region of the Ron enhancer containing 
the SF2/ASF binding site (Mo-SF2) to sterically block the 
binding of this splicing factor and, thus, the skipping of exon 
11. The efficacy of Mo-SF2 was tested using human gastric 
carcinoma KATOIII cells characterized by high levels of 
SF2/ASF, Ron and invasive phenotype. We have found that 
Mo-SF2 inhibits Ron splicing and corrects the cellular 
morphology and the migration properties of the cells [unpub-
lished data]. Alternative Splicing and Tumor Progression  Current Genomics, 2008, Vol. 9, No. 8    567 
CONCLUDING REMARKS 
  Following the sequencing of entire eukaryotic genomes, 
alternative splicing has emerged as the strategy dedicated to 
the interpretation of the genetic information. As widely dis-
cussed in this review, in fact, this mechanism of pre-mRNA 
processing accounts for a large proportion of the proteomic 
diversity in higher eukaryotes. While transcription regulation 
determines the presence and abundance of primary gene 
transcripts, alternative splicing is designed to manipulate the 
message in response to a number of stimuli. In this way it 
may tune protein features, such as the ability to participate to 
hetero-complexes or the sub-cellular localization, in order to 
meet the needs of the cells. Rarely are alternative splicing 
programs associated to “yes or no” decisions; in most of the 
cases splicing products co-exist in a single cell and contrib-
ute to the cell ability to cope with a number of different in-
ternal and external stimuli. From this viewpoint, therefore, 
this mechanism appears to be intimately connected to the 
complexity of metazoan organisms which, once more, un-
derscores the necessity to understand the combinatorial rules 
underlying splice site choices as an obligatory step to reach a 
comprehensive picture of the logic of living matter. 
  Deciphering the biological implications of this regulatory 
process is a challenging task that requires the integration of a 
large body of data relative to the cis-acting sequences and 
trans-acting factors involved, the regulatory circuits and sig-
naling pathways that modulate splice site decisions and fi-
nally the physiological and/or pathological consequences 
resulting from the expression of the various splicing iso-
forms. The attainment of this result will be certainly has-
tened by the recent development of new and highly sophisti-
cated bio-informatics and system biology approaches. 
  An important breakthrough to fully understand how al-
ternative splicing permeates the expression programs is ex-
pected to derive from the application of high-throughput 
methodologies. During the last decade, biomedical sciences 
have been strongly influenced by “omics”: genomics, pro-
teomics, transcriptomic and metabolomic. The application of 
high-throughput approaches to study splicing profiles is just 
at its beginning. This delay is certainly due to a number of 
technical problems deriving from the necessity to contempo-
rary assess for each gene the absolute level of total tran-
scripts and the relative abundance of any splicing isoforms. 
Moreover, the interpretation is significantly complicated by 
the necessity to understand the physiological implications 
resulting from a change in splicing profiles.  
  However, it is easy to predict that this type of analysis 
will provide crucial information to unveil the regulatory 
pathways underlying co-regulation of splicing profiles and to 
understand the relevance of alternative splicing in the con-
text of the organism development. The hope is that splicing-
sensitive arrays will guide the identification of circuits that, 
similarly to signal transduction and transcription pathways, 
may be causatively linked to development programs, or-
ganogenesis, body plan definition and cell identity. Another 
open question concerns the identification of the sub-genome 
that does not undergo alternative splicing events. Do these 
genes identify any particular critical cellular function? 
  Thus, the change of perspective, from detailed charac-
terization of molecular mechanisms to global approaches, it 
is expected to improve our understanding of the physiologi-
cal relevance of alternative splicing and to drastically in-
crease the comprehension of important physiological and 
pathological conditions such as the neuronal plasticity and 
the complexity of cancer. We are confident that system biol-
ogy approaches can help the identification of alternative 
splicing events that may play a critical role in tumor progres-
sion. This will offer the opportunity to develop innovative 
strategies for therapeutical intervention that target specific 
alternative splicing variants. 
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